Clinical Trials
23 trialsNCT06462092 2025-09-29
Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
Guangzhou Medical University
Phase 1/2 Recruiting
NCT05315700 2025-08-05
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
ORIC Pharmaceuticals
Phase 1/2 Recruiting
NCT03242616 2025-04-17
PemVin vs Vin in Previously Treated Metastatic Breast Cancer
Seoul National University Hospital
Phase 2 Completed
NCT01655225 2022-04-08
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02624700 2020-07-14
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT02124148 2020-04-01
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00470548 2018-01-10
Abraxane and Alimta in Advanced Solid Tumors
University of California, Davis
Phase 1/2 Terminated
NCT00703638 2017-11-29
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00006007 2016-12-07
LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02829008 2016-07-12
Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
ChineseAMS
Phase 2 Unknown
NCT01172028 2015-12-03
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
University of Arizona
Phase 1 Completed
NCT00149214 2012-03-21
Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Eli Lilly and Company
Phase 2 Completed
NCT00325234 2011-05-20
Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00190671 2009-11-20
A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients
Eli Lilly and Company
Phase 1/2 Completed
NCT00106002 2009-06-01
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00063570 2009-05-29
Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy
Eli Lilly and Company
Phase 2 Completed
NCT00102219 2007-11-30
A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00065533 2007-06-22
Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00072865 2007-01-26
Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00191347 2007-01-26
A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00034489 2006-07-19
A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.
Eli Lilly and Company
Phase 2 Completed
NCT00097383 2006-07-19
Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer
Eli Lilly and Company
Phase 1/2 Completed